Related Experiment Video
Updated: Nov 22, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated
Nicola Fazio1, Matthew Kulke2, Brad Rosbrook3
1Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Via Ripamonti 435, 20141, Milan, Italy. nicola.fazio@ieo.it.
Background:
Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial.
Objective:
To assess the clinical benefit with sunitinib using the combined data from these trials.
Patients And Methods:
An updated overall survival (OS) in patients with panNETs for the phase IV trial was provided, and an analysis of results from the sunitinib-treated combined cohort from the phase III and IV trials (combined cohort) was conducted to assess PFS, OS, and objective response rate (ORR).
Results:
The updated median OS for the phase IV trial was 54.1 months (95% CI 37.9-not reached). Investigator-assessed median PFS for the combined cohort (n = 102) was 12.9 months (95% CI 7.4-16.7) with a significant benefit versus placebo in the phase III trial (n = 35) (HR 0.429; 95% CI 0.245-0.752; p = 0.001). Median OS could not be calculated for the combined cohort or placebo group due to the high number of patients censored; however, the estimated HR of 0.303 (CI 0.100-0.921; p = 0.013) favored sunitinib. ORR for the combined cohort was 16.7% (95% CI 10.0-25.3). Sunitinib was well tolerated in both trials with a safety profile similar to previously seen in other studies.
Conclusions:
The combined analysis of these studies confirms the objective tumor responses and improvements in PFS observed in the initial phase III trial, providing further support for the clinical benefit of sunitinib in patients with advanced panNETs. CLINICALTRIALS.
Gov Identifiers:
NCT00428597 and NCT01525550.
Insights
Sunitinib demonstrated significant benefits in progression-free survival (PFS) for metastatic pancreatic neuroendocrine tumors (panNETs). Combined data from Phase III and IV trials confirm sunitinib
Area of Science:
- Oncology
- Clinical Pharmacology
- Medical Oncology
Background:
- Sunitinib showed improved progression-free survival (PFS) compared to placebo in metastatic pancreatic neuroendocrine tumors (panNETs) during a Phase III trial.
- The efficacy and safety of sunitinib in panNETs were further validated in an open-label Phase IV clinical trial.
Purpose of the Study:
- To evaluate the overall clinical benefit of sunitinib in patients with panNETs by analyzing combined data from Phase III and IV trials.
- To provide an updated assessment of overall survival (OS) and confirm efficacy metrics including PFS and objective response rate (ORR).
Main Methods:
- Combined analysis of data from a Phase III trial and an open-label Phase IV trial involving patients with panNETs.
- Assessment of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in a combined cohort of sunitinib-treated patients.
- Updated OS data from the Phase IV trial and comparative PFS analysis against placebo from the Phase III trial.
Main Results:
- The updated median OS in the Phase IV trial was 54.1 months. The combined cohort (n=102) showed a median PFS of 12.9 months.
- Sunitinib demonstrated a significant PFS benefit versus placebo in the Phase III trial (HR 0.429, p=0.001).
- The estimated HR for OS favored sunitinib (HR 0.303, p=0.013), and the objective response rate (ORR) was 16.7% in the combined cohort. Sunitinib was well-tolerated.
Conclusions:
- Combined analysis confirms objective tumor responses and improved PFS with sunitinib in advanced panNETs, building upon Phase III findings.
- The results provide further evidence supporting the clinical utility of sunitinib for patients diagnosed with advanced pancreatic neuroendocrine tumors.
- Sunitinib exhibits a favorable safety profile, consistent with previous studies, in the treatment of advanced panNETs.
More Related Videos
12:04Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024